Related Experiment Video
Updated: Jul 8, 2025
05:12
Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
Published on: May 12, 2023
3.7K
Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report
Gurdeep Singh1, Brittany Taylor2, Samantha Michalek2
1Endocrinology, Diabetes and Metabolism, Our Lady of Lourdes Memorial Hospital, Binghamton, USA.
Cureus
|December 19, 2023
Summary
Thyroid eye disease (TED) treatment with teprotumumab may not be effective for all patients. Identifying nonresponse risks is crucial for optimizing care in this autoimmune condition.
Area of Science:
- Ophthalmology
- Endocrinology
- Immunology
Background:
- Thyroid eye disease (TED) is an autoimmune disorder causing orbital inflammation and tissue expansion due to TSH-receptor autoantibodies.
- Insulin-like growth factor 1 (IGF-1) receptors in orbital fibroblasts interact with TSH-receptors, exacerbating TED pathology.
- Teprotumumab (Tepezza) is the sole FDA-approved immunotherapy for TED, targeting IGF-1 receptors.
